Skip to main content
Equibles
MEDS logo

MEDS · DataMeds AI, Inc.

Track MEDS — free

Use MEDS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.80 +1.93 (+223.60%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the date these unaudited condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 17, 2026
Market Cap
$2.65M
Shares
3.06M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.87 Open$0.88 Day$0.86–0.90 Since split$0.85–4.39 Avg vol 30d523K Short int174K · 5.7% float · 1.0d Short vol52% DataMay 2026–Sep 2026 Filing10-Q · Aug 17

Raw chart and full-history price indicators begin at the captured split on May 26, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on May 26, 2026.

Up next

Latest filing: 10-Q
filed Aug 17, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.02M
Trailing 12 months
Net income (TTM)
−$88.28M
Trailing 12 months
Revenue growth YoY
-77.2%
Year over year
Operating margin
-875.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$29.35M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+108.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.7%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Limited Sentiment Bearish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.1 · elevated Equity put/call 0.67
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg −59%
below
RSI (14) 27
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-31% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.68% of float · ▲ +5.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
9 holders — mid 1-yr range
Squeeze score 51
elevated · 0–100
Fundamentals
Weak
Revenue growth +29%
Y/Y
Gross margin -28%
contracting
EPS growth −853%
Y/Y
Balance sheet $23.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 134%
annualized · 1-yr
Max drawdown −81%
past year
ATR 20.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−59% Bearish
RSI (14)
27 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Distributing
-31% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
5.68% of float · ▲ +5.5% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
9 holders — mid 1-yr range
Price context
position in its range since split · 2026-05-26
Range low $1 Now $1 · 0% Range high $4
vs 50-day avg -59%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Distribution — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MEDS
DataMeds AI, Inc.
this stock
$2.65M — +28.7% — 5.7%
MCK
Mckesson Corp
 $106.21B +11.1% +3.1% 24.4 2.4%
COR
Cencora, Inc.
 $62.33B -3.4% +9.3% 24.3 2.4%
CAH
Cardinal Health Inc
 $54.32B +14.3% +14.2% — 2.9%
HSIC
Henry Schein Inc
 $9.91B +17.7% +5.9% 25.9 7.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
9
% held
1.7%
Net QoQ
+9.1K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
174.0K
Days to cover
1.0d
Change
+9.1K sh
View
Short Volume
Short vol %
52%
As of
Sep 14, 2026
Short Total
View
Fails to Deliver
FTD shares
388
Value
$372
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
50.8%
Week of
Aug 10, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$23.3M
Net income (FY)
$-101.3M
EPS diluted
$-71.50
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 18, 2026
This year
32
View

Performance

Raw-price comparisons begin at the captured split on May 26, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
MEDS -5.5% -41.5% — -10.2% —
SPY -1.2% -2.0% +16.1% -0.8% +11.6%
vs SPY -4.3% -39.5% — -9.4% —
Key facts CIK 2030763 CUSIP 949503205 Visit website Investor relations